CS
IOVA icon

Candriam SCA’s Iovance Biotherapeutics IOVA Stock Holding History

Candriam SCA’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-500,033
Closed -$4.7M – 689
2024
Q3 		$4.7M Hold
500,033
– – 0.03% 369
2024
Q2 		$4.01M Sell
500,033
-559,109
-53% -$5.99M 0.02% 371
2024
Q1 		$15.7M Sell
1,059,142
-668,680
-39% -$7.78M 0.1% 198
2023
Q4 		$14M Sell
1,727,822
-1,020,031
-37% -$5.34M 0.1% 215
2023
Q3 		$12.5M Buy
2,747,853
+1,020,037
+59% +$6.66M 0.09% 203
2023
Q2 		$12.2M Buy
1,727,816
+33,896
+2% +$243K 0.09% 221
2023
Q1 		$9.53M Buy
1,693,920
+140,000
+9% +$966K 0.07% 266
2022
Q4 		$9.93M Sell
1,553,920
-115,000
-7% -$898K 0.07% 280
2022
Q3 		$16M Buy
1,668,920
+40,000
+2% +$461K 0.11% 195
2022
Q2 		$18M Buy
1,628,920
+476,335
+41% +$6.24M 0.15% 151
2022
Q1 		$19.2M Buy
1,152,585
+256,221
+29% +$3.96M 0.13% 170
2021
Q4 		$17.1M Buy
896,364
+47,712
+6% +$1.05M 0.11% 194
2021
Q3 		$20.9M Sell
848,652
-171,774
-17% -$4.05M 0.14% 169
2021
Q2 		$26.6M Buy
1,020,426
+428,376
+72% +$11.1M 0.18% 134
2021
Q1 		$26.4M Sell
592,050
-12
-0% -$497 0.22% 121
2020
Q4 		$27.5M Sell
592,062
-93,019
-14% -$3.69M 0.22% 122
2020
Q3 		$22.6M Sell
685,081
-72,575
-10% -$2.22M 0.21% 122
2020
Q2 		$20.8M Buy
757,656
+584,152
+337% +$19.2M 0.22% 115
2020
Q1 		$4.7M Buy
173,504
+26
+0% +$689 0.05% 360
2019
Q4 		$4.8M Buy
173,478
+103,978
+150% +$2.37M 0.05% 367
2019
Q3 		$1.26M Buy
69,500
+21,500
+45% +$475K 0.02% 563
2019
Q2 		$1.17M Buy
+48,000
New +$723K 0.01% 621
2018
Q3 		– Sell
-112,000
Closed -$1.43M – 826
2018
Q2 		$1.43M Buy
112,000
+15,000
+15% +$219K 0.02% 545
2018
Q1 		$1.64M Buy
+97,000
New +$1.47M 0.03% 515

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Candriam SCA's IOVA Position: Q4 2024 in Review

Candriam SCA sold out of Iovance Biotherapeutics (IOVA) in Q4 2024, closing a stake of 500,033 shares — an estimated $4.7M sold.

Candriam SCA first reported a position in IOVA in Q1 2018 and held it in 24 quarters. The position peaked at $27.5M in Q4 2020. 301 funds tracked by Wall St. Rank hold IOVA as of Q4 2024.

  • Candriam SCA reported no remaining Iovance Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • Candriam SCA sold 500,033 Iovance Biotherapeutics shares in Q4 2024, an estimated $4.7M.
  • Candriam SCA first reported a position in Iovance Biotherapeutics in Q1 2018 and held it in 24 quarters.
  • Candriam SCA's Iovance Biotherapeutics position peaked at $27.5M in Q4 2020.
  • 301 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2024.

Based on Candriam SCA's 13F filing for Q4 2024, filed 7 Feb 2025.